SEARCH:   Advanced

Blood, 22 January 2009, Vol. 113, No. 4, pp. 837-845. Prepublished online as a Blood First Edition Paper on November 3, 2008; DOI 10.1182/blood-2008-06-162792. This Article Full Text Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2008-06-162792v1 113/4/837    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gong, G. Articles by Chen, Z. W. Search for Related Content PubMed PubMed Citation Articles by Gong, G. Articles by Chen, Z. W. Related Collections Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Phosphoantigen-activated V2V2 T cells antagonize IL-2–induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection Guangming Gong1,2,*, Lingyun Shao1,*, Yunqi Wang1,*, Crystal Y. Chen1, Dan Huang1, Shuyu Yao1, Ximei Zhan2, Helene Sicard3, Richard Wang1, and Zheng W. Chen1 1 Department of Microbiology and Immunology, Center for Primate Biomedical Research, College of Medicine, University of Illinois at Chicago; 2 Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China; and 3 Innate Pharma, Marseille, France Although Foxp3+ T regulatory cells (Tregs) are well documented for their ability to suppress various immune cells, T-cell subsets capable of counteracting Tregs have not been demonstrated. Here, we assessed phosphoantigen-activated V2V2 T cells for the ability to interplay with Tregs in the context of mycobacterial infection. A short-term IL-2 treatment regimen induced marked expansion of CD4+CD25+Foxp3+ T cells and subsequent suppression of mycobacterium-driven increases in numbers of V2V2 T cells. Surprisingly, activation of V2V2 T cells by adding phosphoantigen Picostim to the IL-2 treatment regimen down-regulated IL-2–induced expansion of CD4+CD25+Foxp3+ T cells. Consistently, in vitro activation of V2V2 T cells by phosphoantigen plus IL-2 down-regulated IL-2–induced expansion of CD4+CD25+Foxp3+ T cells. Interestingly, anti–IFN-–neutralizing antibody, not anti–TGF-β or anti–IL-4, reduced the ability of activated V2V2 T cells to down-regulate Tregs, suggesting that autocrine IFN- and its network contributed to V2V2 T cells' antagonizing effects. Furthermore, activation of V2V2 T cells by Picostim plus IL-2 treatment appeared to reverse Treg-driven suppression of immune responses of phosphoantigen-specific IFN+ or perforin+ V2V2 T cells and PPD-specific IFN+β T cells. Thus, phos-phoantigen activation of V2V2 T cells antagonizes IL-2–induced expansion of Tregs and subsequent suppression of Ag-specific antimicrobial T-cell responses in mycobacterial infection. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020